FDA accepts for review a Karuna Therapeutics NDA for KarXT (xanomeline-trospium) for treating schizophrenia in adults.
Stakeholders comment positively on an FDA draft guidance on developing products to prevent or treat graft-versus-host disease.
A CDER study examines generic nasal spray distribution factors that could speed the development of generic sprays.
FDA clears a Vivos Therapeutics 510(k) for its Vivos CARE (Complete Airway Repositioning and/or Expansion) appliances for treating adults with severe ...
FDA continues to evaluate information about the potential for differences in procedural outcomes between women and men undergoing implant of a left at...
A lengthy online newsletter written by several Skadden attorneys explores possible new theories of cybersecurity False Claims Act liability for life s...
AdvaMed raises concerns about an FDA draft guidance on De Novo electronic submissions.
The Association for Accessible Medicines raises several issues and concerns with FDAs proposal to develop a quality management maturity program.